Fabry Disease: α-Galactosidase A Deficiency

Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition

Volumn , Issue , 2014, Pages 419-430

  Desnick, Robert J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acroparesthesias; Angiokeratoma; Classic and later onset phenotypes; Corneal dystrophy; Enzyme replacement therapy; Globotriaosylceramide; Glycosphingolipids; Lysosomal disease; Galactosidase A deficiency

Indexed keywords

EID: 84943227616     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-410529-4.00038-3     Document Type: Chapter

References (77)

1. Desnick R.J., Ioannou Y.A., Eng C.M. α-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease 2001, 3733-3774. McGraw-Hill, New York. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly (Eds.).
2. Desnick R.J. Fabry disease. Clinical Genomics: Practical Applications in Adult Patient Care 2014, 439-444. McGraw-Hill, New York. M.F. Murray, M.W. Babyatsky, M.A. Giovanni, F.S. Alkuraya, D.R. Stewart (Eds.).
3. Schiffmann R., Murray G.J., Treco D., et al. Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 2000, 97:365-370.
4. Eng C.M., Banikazemi M., Gordon R., et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001, 68:711-722.
5. Eng C.M., Guffon N., Wilcox W.R., et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001, 345:9-16.
6. Schiffmann R., Kopp J.B., Austin H.A., et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285:2743-2749.
7. Wilcox W.R., Banikazemi M., Guffon N., et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004, 75:65-74.
8. Banikazemi M., Bultas J., Waldek S., et al. Agalsidase beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007, 146:77-86.
9. Germain D.P., Waldek S., Banikazemi M., et al. Substained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007, 18:1547-1557.
10. Spada M., Pagliardini S., Yasuda M., et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006, 79:31-40.
11. Lin H.Y., Chong K.W., Hsu J.H., et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2009, 2:450-456.
12. Hwu W.L., Chien Y.H., Lee N.C., et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 2009, 30:1397-1405.
13. Chien Y.H., Lee N.C., Chiang S.C., Desnick R.J., Hwu W.L. Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns-superiority of DNA-based to enzyme-based newborn screening for common mutations. Mol Med 2012, 18:780-784.
14. Wittmann J., Karg E., Turi S., et al. Newborn screening for lysosomal storage disorders in Hungary. JIMD Rep 2012, 6:117-125.
15. Liao H.C., Huang Y.H., Chen Y.J., et al. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A). Clin Chim Acta 2013, 426:114-120.
16. Calzavara-Pinton P.G., Colombi M., Carlino A., et al. Angiokeratoma corporis diffusum and arteriovenous fistulas with dominant transmission in the absence of metabolic disorders. Arch Dermatol 1995, 131:57-62.
17. Dutsch M., Marthol H., Stemper B., et al. Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 2002, 19:575-586.
18. Tan S.V., Lee P.J., Walters R.J., et al. Evidence for motor axon depolarization in Fabry disease. Muscle Nerve 2005, 32:548-551.
19. Üçeyler N., He L., Schönfeld D., et al. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy. J Peripher Nerv Syst 2011, 16:304-314.
20. Sher N.A., Letson R.D., Desnick R.J. The ocular manifestations in Fabry's disease. Arch Ophthalmol 1979, 97:671-676.
21. Nguyen T.T., Gin T., Nicholls K., et al. Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry disease treatment centre. Clin Exp Ophthalmol 2005, 33:164-168.
22. Tøndel C., Bostad L., Laegreid L.M., Houge G., Svarstad E. Prominence of glomerular and vascular changes in renal biopsies in children and adolescents with Fabry disease and microalbuminuria. Clin Ther 2008, 30:S42.
23. Najafian B., Svarstad E., Bostad L., et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int 2011, 79:663-670.
24. Branton M.H., Schiffmann R., Sabnis S.G., et al. Natural history of Fabry renal disease: influence of α-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002, 81:122-138.
25. MacDermot K.D., Holmes A., Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001, 38:750-760.
26. Linhart A., Lubanda J.C., Palecek T., et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 2001, 24(suppl 2):75-83.
27. Fellgiebel A., Muller M.J., Ginsberg L. CNS manifestations of Fabry's disease. Lancet Neurol 2006, 5:791-795.
28. Banikazemi M., Ullman T., Desnick R.J. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 2005, 85:255-259.
29. Germain D.P., Avan P., Chassaing A., et al. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two consecutive hemizygous male patients. BMC Med Genet 2002, 3:10-20.
30. Ries M., Kim H.J., Zalewski C.K., et al. Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain 2007, 130:143-150.
31. Elleder M., Bradova V., Smid F., et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histol 1990, 417:449-455.
32. von Scheidt W., Eng C.M., Fitzmaurice T.F., et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991, 324:395-399.
33. Nakao S., Takenaka T., Maeda M., et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995, 333:288-293.
34. Nakao S., Kodama C., Takenaka T., et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003, 64:801-807.
35. Sachdev B., Takenaka T., Teraguchi H., et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002, 105:1407-1411.
36. Spada M., Pagliardini S. Screening for Fabry disease in end-stage nephropathies. J Inherit Metab Dis 2002, 25(suppl 1):113.
37. Kotanko P., Kramar R., Devrnja D., et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004, 15:1323-1329.
38. Meehan S.M., Junsanto T., Rydel J.J., et al. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications. Am J Kidney Dis 2004, 43:164-171.
39. Rosenthal D., Lien Y.H., Lager D., et al. A novel α-galactosidase A mutant (M42L) identified in a renal variant of Fabry disease. Am J Kidney Dis 2004, 44:85-89.
40. Baptista M.V., Ferreira S., Pinho-E-Melo T. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study-screening genetic conditions in Portuguese young stroke patients. Stroke 2010, 41:431-436. PORTuguese Young STROKE Investigators.
41. Wozniak M.A., Kittner S.J., Tuhrim S., et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 2010, 41:78-81.
42. Opitz J.M., Stiles F.C., Wise D., et al. The genetics of angiokeratoma corporis diffusum (Fabry's disease) and its linkage relations with the Xg locus. Am J Hum Genet 1965, 17:325-342.
43. MacDermot K.D., Holmes A., Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001, 38:769-775.
44. Desnick R.J. Prenatal diagnosis of Fabry disease. Prenatal Diagn 2007, 27:693-694.
45. Aerts J.M., Groener J.E., Kuiper S., et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 2008, 105:2812-2817.
46. van Breemen M.J., Rombach S.M., Dekker N., et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta 1812, 2011:70-76.
47. Matsuura F., Ohta M., Ioannou Y.A., et al. Human α-galactosidase A: characterization of the N-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by Chinese hamster ovary cells. Glycobiology 1998, 8:329-339.
48. Lemansky P., Bishop D.F., Desnick R.J., Hasilik A., von Figura K. Synthesis and processing of alpha-galactosidase A in human fibroblasts: evidence for different mutations in Fabry disease. J Biol Chem 1987, 262:2062-2065.
49. Kornreich R., Desnick R.J., Bishop D.F. Nucleotide sequence of the human α-galactosidase A gene. Nucl Acids Res 1989, 17:3301-3302.
50. Ioannou Y.A., Zeidner K.M., Grace M.E., et al. Human α-galactosidase A: glycosylation site 3 is essential for enzyme solubility. Biochem J 1998, 332:789-797.
51. Froissart R., Guffon N., Vanier M.T., et al. Fabry disease: D313Y is an α-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 2003, 80:307-314.
52. Yasuda M., Shabbeer J., Benson S.D., et al. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat 2003, 22:486-492.
53. Togawa T., Tsukimura T., Kodama T., et al. Fabry disease: biochemical, pathological and structural studies of the α-galactosidase A with E66Q amino acid substitution. Mol Genet Metab 2012, 105:615-620.
54. Lee B.H., Heo S.H., Kim G.H., et al. Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. J Hum Genet 2010, 55:512-517.
55. Ries M., Mengel E., Kutschke G., et al. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J Inherit Metab Dis 2003, 26:413-414.
56. Thadhani R., Wolf M., West M.L., et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002, 61:249-255.
57. Mignani R., Gerra D., Maldini L., et al. Long-term survival of patients with renal transplantation in Fabry's disease. Contrib Nephrol 2001, 229-233.
58. Tsakiris D., Simpson H.K., Jones E.H., et al. Report on management of renal failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 1996, 11:4-20.
59. Ioannou Y.A., Zeidner K.M., Gordon R.E., et al. Fabry disease: preclinical studies demonstrate the effectiveness of α-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 2001, 68:14-25.
60. Lee K., Jin X., Zhang K., et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003, 13:305-313.
61. Sakuraba H., Murata-Ohsawa M., Kawashima I., et al. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 2006, 51:180-188.
62. Togawa T., Takada M., Aizawa Y., Tsukimura T., Chiba Y., Sakuraba H. Comparative study on mannose 6-phosphate residue contents of recombinant lysosomal enzymes. Mol Genet Metab 2014, 111:369-373.
63. Kosch M., Koch H.G., Oliveira J.P., et al. Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease. Kidney Int 2004, 66:1279-1282.
64. Pisani A., Spinelli L., Sabbatini M., et al. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis 2005, 46:120-127.
65. Tøndel C., Bostad L., Larsen K.K., et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 2013, 24:137-148.
66. Fan J.Q., Ishii S., Asano N., et al. Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999, 5:112-115.
67. Fan J.Q. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 2003, 24:355-360.
68. Ishii S., Yoshioka H., Mannen K., et al. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. Biochim Biophys Acta 2004, 1690:250-257.
69. Khanna R., Soska R., Lun Y., et al. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther 2010, 18:23-33.
70. Frustaci A., Chimenti C., Ricci R., et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001, 345:25-32.
71. Benjamin E.R., Khanna R., Schilling A., et al. Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol Ther 2012, 20:717-726.
72. Lukina E., Watman N., Arreguin E.A., et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 2010, 116:4095-4098.
73. Qin G., Takenaka T., Telsch K., et al. Preselective gene therapy for Fabry disease. Proc Natl Acad Sci U S A 2001, 98:3428-3433.
74. Ziegler R.J., Cherry M., Barbon C.M., et al. Correction of the biochemical and functional deficits in Fabry mice following AAV8-mediated hepatic expression of α-galactosidase A. Mol Ther 2007, 15:492-500.
75. Yoshimitsu M., Higuchi K., Ramsubir S., et al. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther 2007, 14:256-265.
76. Anderson W. A case of angiokeratoma. Br J Dermatol 1898, 10:113-117.
77. Fabry J. Ein beitrag zur kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa hemorrhagica Hebrae). Arch Dermatol Syph 1898, 43:187-200.